Scrip
Ranbaxy's US facility gets FDA warning letter
08 February 2010
Anju Ghangurde
The US
FDA's recent warning letter to Ohm Laboratories over good manufacturing practice (GMP) deviations at its plant in Gloversville, New York, includes concerns over certain postmarketing and "unapproved" drug violations, as well as the lack of adequate personnel to ensure the completion of operations...
Please Login to read the full article.
08 February 2010
Anju Ghangurde
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
